



Data Science and Tech Innovation Community of Practice

Purpose and Options for Testing for SARS-Cov2 (the COVID-19 virus):
Considerations for World Bank Task Teams Managing COVID-19 Fast Track Facility Operations

Version 1.0: 9 April, 6pm

For more information, please contact Marelize Gorgens (mgorgens@worldbank.org) or Zara Shubber (zshubber@worldbank.org)

Target audience for this Note:

Task Teams engaged with clients in policy/ program dialogue, project design, and implementation support. This note is intended to serve a range of staff members, including those with professional training in health and generalists working on health. Therefore, it does not emphasize detailed technical specifications, as those are available on websites of specialized agencies. *References to those websites are provided at the end of this note.*

1. Context and Rationales for Testing for COVID-19

For clinical, epidemiological and response planning purposes, diagnostic tests for SARS-CoV-2 (the virus that causes Covid-19 disease) are an important part. Tests for SARS-CoV-2 can be used for different, and sometimes overlapping, purposes, such as:

- *To determine who is currently infected*
 - To provide a basis for isolation and infection prevention and control procedures
 - To enable contact tracing
 - To guide the clinical management of those with symptoms suggestive of COVID-19
- *To determine who has previously been infected*
 - To help build a more complete picture of epidemic course, attack rate, and fatality ratio
 - To help determine the full spectrum of disease severity (for example those with no symptoms or mild symptoms may not have been tested when they were infected)
 - To determine extent of immunity and how long immunity lasts
 - To guide social distancing strategies (for example those who are immune may be able to return to work)
- *For research and surveillance in virology, drug and vaccine development, clinical services, epidemiology, and public health*

2. How to evaluate the accuracy of a test or diagnostic examination: Sensitivity and Specificity

Sensitivity and *specificity* are the two indices used to evaluate the accuracy of a test. As shown in the table below:

- those testing positive who have the disease are called “true positives”;
- those testing positive who **do not** have the disease are called “false positives”;
- those testing negative who have the disease are called “false negatives”; and
- those testing negative who **do not** have the disease are called “true negatives.”

Type of Test	Is the disease present?	
	Yes	No
Positive (indicates the disease is probably present)	A (true positive)	B (false positive)
Negative (indicates the disease is probably absent)	C (false negatives)	D (true negative)
TOTAL	A + C	B + D

Sensitivity = percent of those who have the disease and are so indicated by the test

- $\text{Sensitivity (in percent)} = (A/(A+C)) \times 100$

Specificity = percent of those who **do not** have the disease and are so indicated by the test.

- $\text{Specificity (in percent)} = (D/(B+D)) \times 100$

For all COVID-19 tests, sensitivity and specificity are both important, as they determine the extent to which the test results can be used to draw clinical and epidemiological conclusions, and to understand other evidence that might be needed.

3. Types of Tests Available for COVID-19 Pandemic

The field of testing for SARS-Cov2 is a rapidly evolving field. Nevertheless, there are currently two principal types of tests available, one that amplifies and detects genetic segments of the SARS-CoV-2 virus in respiratory specimens - using a technique called reverse transcription polymerase chain reaction (RT-PCR) - and one that detects the body's immunological response to infection (antibodies) in a blood sample (serological tests).

a) RT-PCR (reverse transcriptase polymerase chain reaction) tests

RT-PCR tests can determine who is currently infected and as such can provide a basis for isolation and infection prevention and control procedures, enable contact tracing and guide the clinical management of those with symptoms suggestive of COVID-19.

RT-PCR is typically very accurate and is generally considered the ‘gold standard’ of diagnostics. It has also been the primary testing method used worldwide as tests are very quick to develop; the first test protocol was developed two weeks after the viral genome sequence was released publicly and formed the basis of the first test kits that were distributed by WHO in January. PCR is a method used widely in molecular biology to make millions to billions of copies of a specific DNA sample rapidly, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail. Reverse transcriptase is a method that transforms RNA into DNA. Because RT-PCR tests (sometimes referred to in literature as ‘swab tests’) rely

on detecting the presence of genetic material of the virus, in this case the RNA of the SARS-CoV-2 virus, it only identifies active infection and cannot identify prior infection in those recovered from COVID-19. As a respiratory tract infection, specimens from the respiratory tract (e.g. a nasal or throat swab or a specimen from the lower respiratory tract such as sputum or fluid from lung washings) are typically used for the SARS-CoV2 PCR test. While a positive result generally confirms diagnosis, a negative result does not exclude infection. False negatives are more likely to occur in early and late infection, with respiratory specimens obtained from the upper (nasal or oral swabs¹) versus lower respiratory tract (sputum or fluid from lung washings)², and in asymptomatic or mild infection, due to lower detectable levels of virus. They can also occur due to technical errors. Data from Wuhan, China, suggest a false negative rate of 11-25% with sputum samples and 27-46% with nasal samples (Yang et al. 2020). If the initial test is negative in a person clinically suspected of having COVID-19, WHO recommends resampling and testing from multiple respiratory tract sites. Normal infection prevention and control precautions should continue and patients must still be advised to isolate. Efforts are ongoing to improve the accuracy of the tests. It is important to note that countries often use different case definitions of suspected cases (i.e. those they consider eligible for testing) and this has been largely driven by testing capacity.

While several countries have adapted the initial WHO protocol targeting different parts of SARS-CoV-2's genetic sequence, the RT-PCR test protocols are generally complex and expensive (e.g. \$60 in India), mainly suited to large, centralized laboratories. It typically takes 4-6 hours for the test to be completed but with the shipment of samples the turnaround time is 24 hours at best. With the large demand for tests resulting in shortages of reagents and limited laboratory capacity and shipping logistics, turn-around times of several weeks have been reported in some areas. To help address this, companies have developed rapid RT-PCR tests that can be conducted in small machines at point of care or near care. These include platforms from Abbott, one from ThermoFisher and another from Cepheid, called the GenXpert platform. These platforms are physical devices located in a laboratory that has to adhere to specific standards. The most common PCR platform in low- and middle-income countries (LMIC) is the GenXpert platform. GenXpert is used for TB testing and HIV viral load testing. Because of the global HIV and TB response, there is an ample supply (sometimes even oversupply) of these devices especially in all the countries that receives development aid for HIV and TB programmes. Calibration of the GenXpert machine for the SARS-Cov2 test is a 15-minute process, done once. Although GenXpert is not typically available point of care in LMIC (i.e. in a facility where healthcare is provided, but rather in a laboratory), laboratory staff know how to use it, and are used to transporting sampling for TB testing. Because of this reason, GenXpert is currently the most feasible testing approach for Africa and South Asia. A SARS-Cov2 Assay by Cepheid currently costs \$198 for 10 tests in LMIC (\$360 in high income countries), though it is estimated that they could cost as low as \$5³. Other testing approaches also exist – see attached in Annex 1.

b) Antibody tests:

Antibody tests can determine who has ever been infected and who may be immune to re-infection. This can be very helpful for guiding strategies for non-pharmaceutical interventions such as social distancing measures. Depending on the timing and accuracy of the test, they can potentially also identify who is currently infected.


An antibody test is one that looks for evidence of the body's immune response to a virus, in this case SARS-Cov2. When someone gets infected with a virus their immune system must work out how to fight it off and

¹ For upper respiratory tract specimens, nasopharyngeal specimens are usually recommended as a minimum (though often people take both nasopharyngeal and oropharyngeal specimens)

² While positivity rate is generally higher for lower respiratory tract specimens, these specimens are typically more difficult to obtain. Not all patients have a productive cough and other specimens typically require a person to be intubated and/or more invasive procedures that are also riskier for the health care worker from an infection prevention control perspective.

³ https://www.treatmentactiongroup.org/wp-content/uploads/2020/04/fair_pricing_webinar_slides_final.pdf

produce substances called antibodies. These are extremely specific and are usually only able to tackle one strain of one virus. For example, if someone has a SARS-Cov2 infection, they will develop anti-SARS-Cov2 antibodies. The body then stores versions of these antibodies in the immune system so that if it comes into contact with that same virus again it should be able to fight it off and probably avoid someone feeling any symptoms at all or only very minor symptoms. To test for these antibodies, a fluid sample (usually blood) is taken from a person and mixed with a reagent that contains part of the virus to see if there is a reaction between the two. If there is a reaction, it means that it is likely that someone has developed antibodies because they were previously infected or are currently infected. If there is no reaction it means they have not had it yet or that it is too early in the infection for the antibodies to have developed. While there are five kinds of antibodies, there are two principal ones linked to immune response that are of particular interest: Immunoglobulin M (IgM), which is the first antibody to appear and represents signs of recent infection, and Immunoglobulin G (IgG), which remains in the body after convalescence (recovery). The illustration below illustrates how this works – noting that the timings of antibody creation for COVID-19 are approximate and still subject to further research. In this discussion, it is important to note that a proportion of persons with COVID-19 infection clears the infection without showing any symptoms (asymptomatic) and some individuals take a few days before they show symptoms (pre-symptomatic).



*Disclaimer: This chart is for illustrative purposes only

Benefits of and limitations with antibody tests: With antibody tests, negative results do not rule out infection; antibodies might not have had enough time to form or the virus could have had a minor amino acid mutation in the epitope recognized by the antibodies screened for in the test. False positives can occur due to cross-reactivity with antibodies from previous infections, such as from other coronaviruses. As such, results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection. But, antibody tests serve other purposes: they help determine whether someone has ever been infected (including for those that may have been asymptomatic and never tested during active infection) and therefore can help provide a more complete picture of the disease burden and fatality ratio. They may also help with assessment of the extent of immunity and how long immunity lasts. Also, if we knew the number of people who have recovered, strategies to ease the social distancing strategies could be planned with more precision, and it can help determine, for example, which health workers should work on the frontline of treating the highest risk patients.

	RT-PCR	Antibody
Purpose	Primarily for clinical purposes	Primarily for epidemiological and programming purposes
Kind of sample needed	Swab typically (nasal and throat) or lower respiratory tract specimen when possible or appropriate (e.g. sputum or fluid from lung washings)	Drop of blood
Can administer point of care?	Yes, if conducted by a PCR device that is available at point of care (some devices are light enough to install at point of care)	Yes, while some methods are done in laboratories, some can work like a pregnancy test kit or A1C level determination – a simple finger prick
Can administer in a self-test kit environment?	No as it needs a PCR device. However, swabs can be self-administered including at home.	Yes, at home or point of care or in a surveillance setting
How long it takes for the test to be administered	It depends: some PCR tests can take several hours, and others can produce results in as early as 15 minutes	Many are rapid test kits and results are available immediately, without a 'device' (like a machine in a laboratory) needed. Some tests will be able to distinguish both IgM and IgG, giving a signal as to the age of the infection.
Cost	Wide range for laboratory based RT-PCR but typically \$50+. Rapid near-care test around \$20 in LMIC.	Inexpensive. As little as \$3

The different test kits and their purposes in the scope of scaling up a country is summarized below:

Test results			Clinical significance
PCR	IgM	IgG	
+	-	-	Patient may be in the window period of infection
+	+	-	Patient may be in the early stage of infection
+	+	+	Patient is in the active phase of infection
+	-	+	Patient may be in the late or recurrent stage of infection
-	+	-	Patient may be in the early stage of infection. PCR result may be false-negative. Antibody test could be false positive
-	-	+	Patient may have had a past infection, and has recovered or antibody test could be false positive
-	+	+	Patient may be in the recovery stage of an infection, or the PCR result may be false-negative. Antibody test could also be false positive.

Source: <https://www.medscape.com/viewarticle/928150>

Other diagnostic options: While viral culture is currently not recommended for safety reasons, testing for **SARS-COV-2 viral load** using PCR may be a promising strategy for the future to help determine prognosis (patients with higher viral load typically have or will develop more severe disease). Radiological imaging (Chest X-ray but especially Chest CT where available, with potential for these to be read by AI) may be helpful in making the diagnosis, but no finding can completely rule in or rule out the possibility of COVID-19. Classic signs of CV-induced pneumonia are described as 'ground glass' opacification. Other testing approaches are

also being considered and reviewed by scientists. For example, CRISPR diagnostic methods that work in a similar way to RT-PCR in that they can identify segments of the virus are in the pipeline.

4. Procurement of test kits and related laboratory paraphernalia

Test kits can be procured by countries through the WHO, UNICEF, or the Global Drug Facility (GDF). A specific point to note about using the Cepheid SARS-Cov2 tests on the GeneXpert platform: The GDF also enables the procurement of the biosafety level II storage devices, which is needed when the GeneXpert machines are used for COVID-19 testing. It was confirmed that the GDF that will include cartridges for rapid testing of COVID-19 in their catalogue of medicines available to the public sector. LMICs that already procure supplies through the GDF will have quicker and more equitable access to COVID-19 test kits. There are more than 23,000 automated GeneXpert® Systems worldwide. The use of GeneXpert was welcomed by the TB community but with 2 caveats: (a) to avoid cross contamination, it is recommended that GeneXpert machines be dedicated to COVID-19 testing only; and b) the use of GeneXpert for COVID-19 testing should not interrupt the TB testing, which is also necessary and should continue. A solid supply chain of both kinds of tests should be maintained. See Annex B for a detailed write up about GeneXpert's use for COVID-19 testing.

5. Helping countries decide which test kits to use

WHO manages a Diagnostics Supply Consortium, in which the WB is represented. For normative guidance on diagnostics, the local WHO representative should be contacted for advice, or you can contact Zara Shubber (zshubber@worldbank.org). That said, WB task teams can help countries ask the right questions. Decisions about testing:

- a) Purpose of testing – for clinical or epidemiological and programming purposes
- b) Laboratory capacity and logistics of laboratory supplies
- c) Volume and kind of PCR machines already available in the country
- d) Physical location of the PCR machines
- e) Donated test kits available
- f) Test kits available through the different pooled procurements
- g) Test kit approval status – test kits not pre qualified by WHO requires a 2nd sample to be taken and sent to a WHO reference laboratory before the case will be noted as a confirmed case by WHO
- h) Any other advice from WHO

In summary, there are different tests available for COVID-19 diagnostics, each with their benefits and limitations. Task teams are encouraged to consider these benefits and limitations along with the country objectives and realities on the ground.

For more information and the latest updates on laboratory testing for COVID-19 infection, please refer to:

- **Coronavirus disease (COVID-19) technical guidance:** Laboratory testing for 2019-nCoV in humans. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>
- **CDC Tests for COVID-19.** <https://www.cdc.gov/coronavirus/2019-ncov/about/testing.html>

Annex A: Test Kit Options from WHO Diagnostics Consortium

Manufacturer	Type of Test	Technical Notes	Sample Collection Type	Test Target	Test Designation (Lab or RDT)	Country Approved (incl EUAs)	CE Certified	Source
CDC	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Wadsworth Center, NYSDOH	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Roche cobas	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA	CE mark	FDA Website
Thermo Fisher Scientific, Inc.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA	CE mark	FDA Website
Hologic, Inc.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Laboratory Corporation of America	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Quidel Corp.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Quest Diagnostics Infectious Disease, Inc.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Abbott Molecular	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
DiaSorin Molecular LLC	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
GenMark Diagnostics, Inc.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Primerdesign Ltd	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Cepheid (Point of care test)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider does not need to be sent to lab	Swab of nose and throat	Viral RNA	Lab test	USA	CE Mark	FDA Website
BioFire Defense, LLC	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Mesa Biotech Inc.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
PerkinElmer, Inc.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	USA		FDA Website
Roche Molecular Systems Inc.	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	Canada		Government of Canada Website
ThermoFisher Scientific	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	Canada	CE Mark	Government of Canada Website
Luminarie Canada Inc. (SK)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	Canada		Government of Canada Website
Diagnostic Hybrids, Inc. (US)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	Canada		Government of Canada Website
Hangzhou Alltest Biotech Co., Ltd. (China)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	Canada		Government of Canada Website
Life Sciences Research Institute (South Korea)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	Canada		Government of Canada Website
Hologic (United States)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab test	Canada		Government of Canada Website

Cepheid (United States)	Lab and POC based PCR	Lab based test to be collected by trained professional. POC means at point of care including doctor's office lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Swab of nose and throat	Viral RNA	Lab test and POC	Canada	Government of Canada Website
Hangzhou Alltest Biotech Co Ltd (China)	Lateral Flow IgG/IgM		Blood	Antibody Test	Rapid Diagnostic	Australia	Government of Canada Website
AusDiagnostics Pty Ltd (Australia)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Australia	Government of Canada Website
Roche Molecular Systems Inc (USA)	Nucleic Acid Test	Lab test. Taken by trained provider lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Swab of nose and throat	Viral RNA	Lab diagnostic test	Australia	Government of Canada Website
VivaCheck Biotech (Hangzhou) Co Ltd (China)	Lateral Flow IgG/IgM		Blood	Antibody Test	Rapid Diagnostic	Australia	Government of Canada Website
Shanghai ZJ Bio-Tech Co Ltd (China)	Nucleic Acid Test	Lab test. Taken by trained provider lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Swab of nose and throat	Viral RNA	Lab diagnostic test	Australia	Government of Canada Website
CTK Biotech Inc (USA)	Lateral Flow IgG/IgM		Blood	Antibody Test	Rapid Diagnostic	Australia	Government of Canada Website
Hologic Inc (USA)	Nucleic Acid Test	Lab test. Taken by trained provider lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Swab of nose and throat	Viral RNA	Lab diagnostic test	Australia	Australian Government Health Department
Guangzhou Wondfo Biotech Co Ltd (China)	Lateral Flow IgG/IgM		Blood	Antibody Test	Rapid Diagnostic	Australia	Australian Government Health Department
Life Technologies Corporation (USA)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Australia	Australian Government Health Department
CerTest Biotec SL (Spain)	Nucleic Acid Test	Lab test. Taken by trained provider lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Swab of nose and throat	Viral RNA	Lab diagnostic test	Australia	Australian Government Health Department
VivaChek Biotech (Hangzhou) Co Ltd (China)	Lateral Flow IgG/IgM		Blood	Antibody Test	Rapid Diagnostic	Australia	Australian Government Health Department

Guangzhou Wondfo Biotech Co Ltd (China)	Lateral Flow IgG/IgM	lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Blood	Antibody Test	Rapid Diagnostic	Australia	Australian Government Health Department
Cepheid (USA)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Australia	Australian Government Health Department
kogenebiotech (South Korea)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	South Korea	Sheet Provided
Seegene (South Korea)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	South Korea	Sheet Provided
SolGent Co.,Ltd. (South Korea)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	South Korea	Sheet Provided
SD BIOSENSOR (South Korea)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	South Korea	Sheet Provided
BioSewoom Inc. (South Korea)	Nucleic Acid Test	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	South Korea	Sheet Provided
Diagnostics Development Hub (DxD) (Singapore)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	Singapore Health Science Authority Website
Veredus Laboratories Pte Ltd (Singapore)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	Singapore Health Science Authority Website
AITbiotech Pte Ltd (Singapore)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	Singapore Health Science Authority Website
DSO National Laboratories (Singapore)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	Singapore Health Science Authority Website
Roche Diagnostics Asia Pacific Pte Ltd	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	Singapore Health Science Authority Website
JN Medsys Pte Ltd (Singapore)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	Singapore Health Science Authority Website
Life Technologies Holdings Pte Ltd (Singapore)	Real-Time RT-PCR Diagnostic Panel	Lab test. Taken by trained provider	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	Singapore Health Science Authority Website
Everest Links Pte Ltd (Singapore)	IgM/IgG Rapid Test	lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Blood	Antibody Test	Rapid Diagnostic	Singapore	Singapore Health Science Authority Website
Biolidics Limited (Singapore)	IgG/IgM Detection Kit	lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies	Blood	Antibody Test	Rapid Diagnostic	Singapore	Singapore Health Science Authority Website

		Loop-mediated isothermal amplification (LAMP) is a method that can amplify DNA under isothermal conditions.					
Biowalker Pte Ltd (Singapore)	Isothermal Amplification-Real Time Fluorescence Assay	Helps avoid false-positives Lab test. Taken by trained provider.	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	
SPD Scientific Pte Ltd (Singapore)	Real-Time RT-PCR Diagnostic Panel	Subject to false positives Lab test. Taken by trained provider.	Swab of nose and throat	Viral RNA	Lab diagnostic test	Singapore	
Shanghai Liferiver Bio-Tech (United States) Corp	Real-Time RT-PCR Diagnostic Panel	Subject to false positives Lab test. Taken by trained provider.	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
Shanghai GeneoDx Biotech Co., Ltd.	Real-Time RT-PCR Diagnostic Panel	Subject to false positives	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
BGI Tech (Wuhan) Co., Ltd.	cPAS, combinatorial probe-anchor synthesis sequencing method		Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
BGI Tech (Wuhan) Co., Ltd.	fluorescent PCR method	Lab test. Taken by trained provider. Subject to false positives Lab test. Taken by trained provider.	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
Da An Gene Co., Ltd.	fluorescent PCR method	Subject to false positives Lab test. Taken by trained provider.	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
Sansure Biotech	fluorescent PCR method	Subject to false positives Lab test. Taken by trained provider.	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
Shanghai BioGerm	fluorescent PCR method	Subject to false positives	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
Guangzhou Wondfo Biotech Co., Ltd.	Antibody Test Kit (Colloidal gold method)	Ten-minute lateral flow immunoassay that detects IgM and IgG antibodies directed against SARS-CoV-2 Ten-minute lateral flow immunoassay that detects IgM and IgG antibodies directed against SARS-CoV-3	Blood	Antibody Test	Rapid Diagnostic	China	
Innovita (Tangshan) Biotech Co., Ltd.	Antibody Test Kit (Colloidal gold method)	Ten-minute lateral flow immunoassay that detects IgM and IgG antibodies directed against SARS-CoV-3	Blood	Antibody Test	Rapid Diagnostic	China	
Chengdu Capital Biotech Co., Ltd.	Virus Nucleic Acid Detection Kit (isothermal amplification chip method)	PCR	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
Beijing X-ABT Biotech Co., Ltd.	fluorescent PCR method	PCR	Swab of nose and throat	Viral RNA	Lab diagnostic test	China	
Bioscience (Chongqing) Biotech Co., Ltd.	IgM Antibody Test Kit (magnetic particle chemiluminescence method)	Most effective for accurate infection	Blood	Antibody Test	Rapid Diagnostic	China	

[Singapore Health Science Authority Website](#)
[Singapore Health Science Authority Website](#)

Bioscience (Chongqing) Biotech Co., Ltd.	IgG Antibody Test Kit (magnetic particle chemiluminescence method)	Can show if ever exposed Lab test. Taken by trained provider.	Blood	Antibody Test	Rapid Diagnostic	China
Maccura Biotech Co., Ltd.	fluorescent PCR method	Subject to false positives	Swab of nose and throat	Viral RNA	Lab diagnostic test	China
Xiamen InnoDx Biotech Co., Ltd.	Antibody Test Kit (CLIA method)	Antibody test kit with fluorescence	Blood	Antibody Test	Rapid Diagnostic	China
Guangdong Hecin Biotech Co., Ltd.	IgM Antibody Test Kit (colloidal gold method)	Ten-minute lateral flow immunoassay that detects IgM and IgG antibodies directed against SARS-CoV-3 Lab test. Taken by trained provider.	Blood	Antibody Test	Rapid Diagnostic	China
Wuhan Easy Diagnosis Biomedicine Co., Ltd.	PCR Kit (fluorescent PCR method)	Subject to false positives Ten-minute lateral flow immunoassay that detects IgM and IgG antibodies directed against SARS-CoV-3	Swab of nose and throat	Viral RNA	Lab diagnostic test	China
Nanjing Vazyme Biotech Co., Ltd.	IgM/IgG Antibody Test Kit (colloidal gold method)	Ten-minute lateral flow immunoassay that detects IgM and IgG antibodies directed against SARS-CoV-3	Blood	Antibody Test	Rapid Diagnostic	China
Zhuhai Livzon Pharmaceutical Group Inc.	IgM/IgG Antibody Test Kit (colloidal gold method)	SARS-CoV-3	Blood	Antibody Test	Rapid Diagnostic	China
CERTEST BIOTEC SL - SPAIN Equipamentos E Suprimentos Hospitales LTDA - CNPJ	VIASURE SARS-CoV-2 Real-Time PCR Detection Kit		Blood	Antibody Test	Rapid Diagnostic	Brazil
GUANGZHOU WONDFO BIOTECH CO., LTD. - CHINA, PEOPLE'S REPUBLIC CELER BIOTECNOLOGIA S / A	One Step COVID-2019 Test	IgM/IgG antibody test	Blood	Antibody Test	Rapid Diagnostic	Brazil
GUANGZHOU WONDFO BIOTECH CO., LTD - CHINA, PEOPLE'S REPUBLIC DIAGNÓSTICA INDÚSTRIA E COMÉRCIO LTDA - ME	IgM/IgG antibody test		Blood	Antibody Test	Rapid Diagnostic	Brazil
EBRAM PRODUTOS LABORATORIAIS LTDA - BRAZIL	IgG / IgM		Blood	Antibody Test	Rapid Diagnostic	Brazil
Eco Diagnostica Ltda - BRAZIL Eco Diagnostica Ltda	ECO F COVID-19 Ag	Ag	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	Brazil
Eco Diagnostica Ltda - BRAZIL Eco Diagnostica Ltda	IgG / IgM ECO Test		Blood	Antibody Test	Rapid Diagnostic	Brazil
Eco Diagnostica Ltda - BRAZIL Eco Diagnostica Ltda	Ag ECO Test		Swab of nose and throat	Viral Antigen	Rapid Diagnostic	Brazil
LABTEST DIAGNOSTICA S / A - BRAZIL LABTEST DIAGNOSTICA S / A	IgG / IgM Rapid Test		Blood	Antibody Test	Rapid Diagnostic	Brazil
HANGZHOU BIOTEST BIOTECH CO., LTD. - CHINA, PEOPLE'S REPUBLIC LUMIRADX HEALTHCARE LTDA	LUMIRATEK COVID-19 (IgG / IgM)		Blood	Antibody Test	Rapid Diagnostic	Brazil
HANGZHOU BIOTEST BIOTECH CO., LTD. - CHINA, PEOPLE'S REPUBLIC MEDLEVENSOHN COMÉRCIO E REPRESENTAÇÕES DE PRODUTOS HOSPITALARES LTDA	MedTest Coronavirus (COVID-19) IgG / IgM		Blood	Antibody Test	Rapid Diagnostic	Brazil
MOBIUS LIFE SCIENCE INDÚSTRIA E COMERCIO DE PRODUTOS PARA LABORATÓRIOS LTDA - BRAZIL	FAMILY KIT XGEN MASTER COVID-19 - Master Kit for Detection of the SARS-CoV-2 Coronavirus RT-qPCR		Swab of nose and throat	Viral RNA	Lab diagnostic test	Brazil
ORANGELIFE COMÉRCIO E INDÚSTRIA LTDA - BRAZIL	DPP® COVID-19 IgM / IgG System		Blood	Antibody Test	Rapid Diagnostic	Brazil

ACRO BIOTECH INC. - USA QR Consulting, Import and Distribution of Medical Products Ltda	Family Rapid Test Cassette 2019-nCoV IgG / IgM (whole blood / serum / plasma)		Blood	Antibody Test	Rapid Diagnostic Lab diagnostic test and Point of Care	Brazil		
ROCHE MOLECULAR SYSTEMS, INC. - USA SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD (SNIBE) - CHINA, PEOPLE'S REPUBLIC VR MEDICAL IMPORTADORA E DISTRIBUIDORA DE PRODUTOS MÉDICOS LTDA SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD (SNIBE) - CHINA, PEOPLE'S REPUBLIC VR MEDICAL IMPORTADORA E DISTRIBUIDORA DE PRODUTOS MÉDICOS LTDA VYTTRA DIAGNOSTICOS IMPORTACAO E EXPORTACAO SA - BRAZIL	Cobas family SARS-CoV-2	PCR Test	Swab of nose and throat	Viral RNA		Brazil		
Viasure Sars-CoV-2 real time PCR detection kit, developed under a partnership between Becton Dickinson and the much smaller group Certest Biotec.	IgG-nCoV (CLIA)		Blood	Antibody Test	Rapid Diagnostic	Brazil		
	IgM-nCoV (CLIA)		Blood	Antibody Test	Rapid Diagnostic	Brazil		
	Covid-19 Vyttra Smart Test		Blood to Serum	Antibody Test	Rapid Diagnostic	Brazil		
	Real-Time PCR assay	PCR	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Novacyt (British-French)	Real-Time PCR assay	PCR	Swab of nose and throat	Viral RNA	Lab Test	Emergency authorization in US and will make in UK	CE Mark	News
Co-Diagnostics (Utah, USA)	Real-Time PCR assay	PCR	Swab of nose and throat	Viral RNA	Lab Test	USA	CE Mark	News
1drop Inc	qPCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
AB Analitica	Nucleic Acid Test	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Beijing Applied Biological Technologies Co. Lts	Multiple Real-Time PCR	Lab and POC	Swab of nose and throat	Viral RNA	Lab Test and POC		CE Mark	
Beijing Kewei Clinical Diagnostic Reagent Inc.	Nucleic Acid Test	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Cancer Rop Co., Ltd.	RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Chaozhou Hybribio Biochemistry Ltd.,	RT-PCR manual & automated lab-based	manual & automated lab-based	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Clonit		Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
CTK Biotech, Inc.	RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Daan Gene Co., Ltd. of Sun Yat-sen University	Real Time Multiplex RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Edinburgh Genetics Limited	RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Eurobio Scientific	Real Time Multiplex RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Gencurix Inc.	Nucleic acid test	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Getein Biotech, Inc.	RT-PCR Kit	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
KH Medical Co. Ltd,	Real Time Multiplex RT-PCR?	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
KogeneBiotech Co. Ltd	RT-PCR Kit	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Liferiver	Real Time Multiplex RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Liming Bio-Products Co.	Real Time Multiplex RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	
Nanjing Vazyme Medical Technology Co., LTD.	Triplex RT-qPCR	Lab	Swab of nose and throat	Viral RNA	Lab Test		CE Mark	

Novacyt/Primerdesign Ltd	RT-PCR Kit	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
PerkinElmer Inc.	RT-PCR Kit	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Sansure Biotech, Inc.	PCR-Fluorescence Probing	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
SD BIOSENSOR Inc.	RT-PCR Kit	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Shaanxi Lifegen Co., Ltd.	fluorescent PCR method	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Shenzhen Puruikang Biotech Co., Ltd	RT-PCR-Fluorescence Probing	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Shenzhen Tailored Medical Ltd	PCR-Fluorescent Probe Method	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Vircell, S.L.	RT-PCR	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Wuhan Easydiagnosis Biomedicine Co., Ltd	Nucleic acid test	Lab	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
3D Medicine Science & Technology Co., Ltd.	RT-qPCR	Automated lab-based, near-POC NAT or POC NAT	Swab of nose and throat	Viral RNA	Lab Test or POC	CE Mark
AITbiotech	qPCR	lab based	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Anatolia Geneworks	Multiplex Nucleic Acid Detection Kit for Respiratory Pathogens	lab based	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Bai-care			Swab of nose and throat	Viral RNA	Lab Test	CE Mark
Beijing Microread Genetics Co.,Ltd,		lab-based or near-POC	Swab of nose and throat	Viral RNA	Lab Test or POC	CE Mark
BIONEER Corporation	RT-PCR	lab based automated kit	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
CerTest Biotec, S.L.	RT-PCR	lab-based or near-POC	Swab of nose and throat	Viral RNA	Lab Test	CE Mark
QIAGEN GmbH			Swab of nose and throat	Viral RNA	Lab Test or POC	CE Mark
Beijing Savant Biotechnology Co., Ltd.	Antigen Fluorescence Rapid Detection Kit		Swab of nose and throat	Viral RNA	Rapid Diagnostic	CE Mark
Epitope Diagnostics, Inc.	IgG ELISA Kit	(manual; automated; CE-IVD)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Epitope Diagnostics, Inc.	IgM ELISA Kit		Blood	Antibody Test	Rapid Diagnostic	CE Mark
EUROIMMUN AG	ELISA (IgA)		Blood	Antibody Test	Rapid Diagnostic	CE Mark
EUROIMMUN AG	ELISA (IgG)	(manual; automated; CE-IVD)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Liming Bio-Products Co., Ltd	Antigen Rapid Test Device		Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
LOMINA AG.	IgM/IgG Antibody Fast Detection Kit		Blood	Antibody Test	Rapid Diagnostic	CE Mark
SD BIOSENSOR, Inc.	Ag FIA (manual		Swab of nose and throat	Antigen	Rapid Diagnostic	CE Mark
Shenzhen Yhlo Biotech Co. Ltd	IgM antibody test		Blood	Antibody Test	Rapid Diagnostic	CE Mark
Shenzhen Yhlo Biotech Co. Ltd	IgG antibody test		Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sugentech, Inc.	IgM/IgG antibody test		Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sugentech, Inc.	IgM antibody test		Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sugentech, Inc.	IgG antibody test		Blood	Antibody Test	Rapid Diagnostic	CE Mark
Taizhou ZECEN Biotech Co.	IgM antibody test		Blood	Antibody Test	Rapid Diagnostic	CE Mark
Taizhou ZECEN Biotech Co.	IgG antibody test		Blood	Antibody Test	Rapid Diagnostic	CE Mark
	IgM/IgG test kit (Rare Earth Nano Fluorescence					
AmonMed Biotechnology Co., Ltd.	Immunochromatography)		Blood	Antibody Test	Rapid Diagnostic	CE Mark
AmonMed Biotechnology Co., Ltd.	IgM/IgG test kit (Colloidal Gold)		Blood	Antibody Test	Rapid Diagnostic	CE Mark

	COVID-19/Influenza A virus/Influenza B virus IgM combo test kit (Rare Earth Nano Fluorescence Immunochromatography)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
AmonMed Biotechnology Co., Ltd.	COVID-19/Influenza A virus/Influenza B virus test kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
AmonMed Biotechnology Co., Ltd.	COVID-19 Antigen Test Kit	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
	COVID-19 Antibody (IgG/IgM) Test Kit (Colloidal Gold Immunochromatography)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Beijing Abace Biology Co., Ltd	IgG Antibody Determination Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Beijing Diagreat Biotechnologies Co., Ltd.	IgM Antibody Determination Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Beijing Diagreat Biotechnologies Co., Ltd.	IgM ELISA Test Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Beijing Kewei Clinical Diagnostic Reagent Inc.	IgG ELISA Test Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Beijing Kewei Clinical Diagnostic Reagent Inc.	IgG/IgM Fluorescence Rapid Test Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Beijing Kewei Clinical Diagnostic Reagent Inc.	Antigen ELISA Test Kit (Nasal/Throat Swab)	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
Beijing Kewei Clinical Diagnostic Reagent Inc.	Antigen Fluorescence Rapid Test Kit (Nasal/Throat Swab)	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
	Combo IgM/IgG Rapid Test (Lateral Flow Method)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Beijing Tigsun Diagnostics Co., Ltd.	IgG/IgM Rapid Test Cassette	Blood	Antibody Test	Rapid Diagnostic	CE Mark
BIOMAXIMA S.A.	COVID-19 IgM-IgG Dual Antibody Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
BioMedomics, Inc.	Cellex qSARS-CoV-2 IgG/IgM Cassette Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Cellex, Inc.	Antibody Test Strip (Colloidal Gold Method)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Changsha Sinocare Inc.	IgM/IgG Ab Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Core Technology Co., Ltd.	IgG/IgM Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
CTK Biotech, Inc.	IgG/IgM Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Dynamiker Biotechnology (Tianjin) Co., Ltd.	novel coronavirus antibody detection reagent (Colloidal gold)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Edinburgh Genetics Limited	IgM/IgG	Blood	Antibody Test	Rapid Diagnostic	CE Mark
GenBody, Inc.	IgM/IgG DUO	Blood	Antibody Test	Rapid Diagnostic	CE Mark
GenBody, Inc.	IgM/IgG antibody (Colloidal Gold)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Getein Biotech, Inc.	IgG/IgM Detection Kit (Colloidal Gold)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Hangzhou AllTest Biotech Co., Ltd	Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Innovita Biological Technology Co. Ltd	Ag Rapid Test Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Jiangsu Bioperfectus Technologies Co. Ltd	IgM/IgG Rapid Test Kit	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
Jiangsu Bioperfectus Technologies Co. Ltd	COVID-19 IgG/IgM Combo Rapid Test Device	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Liming Bio-Products Co., Ltd	IgM/IgG Rapid Test Cassette	Blood	Antibody Test	Rapid Diagnostic	CE Mark
MedicalSystem Biotechnology Co., Ltd.	IgG/IgM Rapid Test Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Nantong Egens Biotechnology Co., LTD	Antibody Detection Kit (Colloidal Gold Immunochromatographic assay)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
PerGrande BioTech Development Co., Ltd.	Coronavirus (SARS-CoV-2)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
RayBiotech	IgM/IgG Test Kit (Colloidal Gold)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
SD BIOSENSOR, Inc.	STANDARD Q COVID-19 IgM/IgG Duo Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
SD BIOSENSOR, Inc.	STANDARD Q COVID-19 Ag Test	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
SensingSelf, Pte, Ltd, Singapore,	Rapid Test Kit (IgM/IgG)	Blood	Antibody Test	Rapid Diagnostic	CE Mark

Shanghai Chemtron Biotech Co. Ltd.	IgM Antibody Diagnostic Kit (Colloidal gold)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Shenzhen Bioeasy Biotechnology Co., Ltd.	Fluorescence Antigen Rapid Test	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
Shenzhen Bioeasy Biotechnology Co., Ltd.	Colloidal Gold Antigen Rapid Test IgG/IgM detection kit (colloidal gold immunochromatography)	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
Shenzhen Bioeasy Biotechnology Co., Ltd.	Ag Fluorescence Rapid Test Kit (Time-Resolved Fluorescence)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Shenzhen Bioeasy Biotechnology Co., Ltd.	IgM/IgG Antibody Assay Kit (Colloidal Gold Method)	Swab of nose and throat	Viral Antigen	Rapid Diagnostic	CE Mark
Shenzhen Tailored Medical Ltd.	IgM/IgG	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sugentech, Inc.	IgM	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sugentech, Inc.	IgG	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sure Bio-Tech (USA) Co., Ltd.	IgM Ab Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sure Bio-Tech (USA) Co., Ltd.	IgG Ab Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Sure Bio-Tech (USA) Co., Ltd.	IgM/IgG Ab Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Tianjin MNCHIP Technologies Co., Ltd.	IgM/IgG rapid test kit (Colloidal gold assay)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
VivaChek Biotech (Hangzhou) Co., Ltd	VivaDiag COVID-19 IgM/IgG Rapid Test	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Wuhan EasyDiagnosis Biomedicine Co.,Ltd	IgM antibody test kit (colloidal gold method)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Wuhan EasyDiagnosis Biomedicine Co.,Ltd	IgG antibody test kit (colloidal gold method)	Blood	Antibody Test	Rapid Diagnostic	CE Mark
Xiamen Biotime Biotechnology Co., Ltd.	IgG/IgM Rapid Qualitative Test Kit	Blood	Antibody Test	Rapid Diagnostic	CE Mark

Annex B: The Use of GeneXpert



Rapid communication on the role of the GeneXpert[®] platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region

**European Laboratory Initiative
on TB, HIV and Viral Hepatitis**

1 April 2020

Abstract

In view of the current COVID-19 pandemic and consequent need for automated rapid diagnostic technologies with a rapid turnaround time, the European Laboratory Initiative on TB, HIV and Viral Hepatitis (ELI) has developed this rapid communication to inform Member States of the WHO European Region on the potential use of the Xpert® Xpress SARS-CoV-2 cartridge (Cepheid, Sunnyvale, United States of America). These cartridges, which received Emergency Use Authorization from the United States Food and Drug Administration on 20 March 2020, can be run on GeneXpert® platforms that are already available in the Region and currently used for diagnosis of tuberculosis and rifampicin resistance (as recommended by WHO), hepatitis C and seasonal influenza, and for HIV viral load testing and early infant diagnosis of HIV infection. Based on the best available evidence and current knowledge, this rapid communication by ELI provides a short overview of (i) the major points when considering the use of GeneXpert machines for COVID-19 testing and (ii) the support that ELI is working to provide to Member States of the Region.

Address requests about publications of the WHO Regional Office for Europe to:

Publications
WHO Regional Office for Europe
UN City, Marmorvej 51
DK-2100 Copenhagen Ø, Denmark

Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (<http://www.euro.who.int/pubrequest>).

Rapid communication on the role of the GeneXpert® platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Rapid communication on the role of the GeneXpert® platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region. Copenhagen: WHO Regional Office for Europe; 2020. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Background

On 30 January 2020 WHO declared coronavirus disease 2019 (COVID-19) a public health emergency of international concern, and on 11 March declared it as a global pandemic. From the onset of this public health crisis, the need for rapid and accurate laboratory testing was highlighted, and laboratory scientists responded by developing the first diagnostic tests for COVID-19 within days of the release of the viral genome sequence.

The WHO European Region is currently the epicentre of the COVID-19 outbreak, with the disease reportedly most prevalent in the western part of the Region; however, this information needs to be carefully interpreted because countries are in different stages of disease transmission and the lower numbers reported in some eastern European countries may be due to the lack of available diagnostic services. All countries need to plan ahead to ensure sufficient diagnostic capacity, as outlined in the WHO guidance document, Laboratory testing strategy recommendations for COVID-19.¹

In this context, one of the key questions faced by countries is which diagnostic assay(s) to adopt to meet the demand for the four transmission scenarios identified by WHO (1,2). Serological or rapid antigen tests are currently not recommended by WHO for COVID-19 case detection: instead, nucleic acid amplification tests should be used. However, this guidance may change based on the availability of new serological tests (1). An overview of tests under development can be found on the FIND website (3). Some have already received Emergency Use Authorization by the United States Food and Drug Administration (FDA) and/or are CE-IVD marked² for diagnostic use in the European Union. WHO is continuously updating technical guidance for COVID-19, including recommendations on laboratory testing (2). No comprehensive comparison of the performance of rapid diagnostic has been performed to date, although several evaluations are ongoing or planned (5). For the time being, the following logistic and financial factors, among other factors, can be weighed to inform the choice of nucleic acid amplification test: turnaround time, throughput (i.e. number of tests that can be run simultaneously in one round), degree of automation, supply considerations and cost (list not exhaustive).

Key updates and considerations

COVID-19 testing with the Xpert® Xpress SARS-CoV-2 cartridge

In view of FDA Emergency Use Authorization of the Xpert® Xpress SARS-CoV-2 cartridge (Cepheid, Sunnyvale, United States of America) (6,7) on 20 March 2020, one option for COVID-19 testing may be to leverage the spare capacity of existing GeneXpert® machines. Possible advantages of this approach are that the assay is fully automated and provides results within

¹ For the latest update, please check the following version of the document, Laboratory testing strategy recommendations for COVID-19. Interim guidance: 22 March 2020 (1).

² CE marking is required for all in vitro diagnostic (IVD) devices sold in Europe. It indicates that an IVD device complies with the European In-Vitro Diagnostic Devices Directive (98/79/EC) and that the device may be legally commercialized in the European Union (4).

45 minutes. Laboratory staff may be already familiar with the GeneXpert® platform, given that the Xpert® MTB/RIF assay serves as the primary diagnostic assay for tuberculosis (TB) and its drug-resistant forms in eastern and central European countries in accordance with WHO recommendations (8). Therefore, the possibility of applying GeneXpert® platforms can be considered providing cartridge production capacity and cost are optimal. However, it is important to note that according to WHO guidelines and recommendations GeneXpert®-based COVID-19 testing should not be used outside of laboratories with adequate containment practices, which may diminish the value of the rapid turnaround time in the absence of efficient sample transport/logistics (9). Moreover, the WHO Emergency Use Listing procedure is ongoing (timeline for completion is not yet known) (10,11) and there is a possibility that the cartridge will not be endorsed or will be reserved only for narrow applications. Moreover, the throughput of Xpert® Xpress SARS-CoV-2 is limited (e.g. in a machine with four modules, only four tests can be done with a turnaround time of 45 minutes). Assuming one test is performed per module per hour and a 24-hour working pattern, the total theoretical capacity of 10 GeneXpert® machines with four modules would be approximately 960 samples per day. Crucially, however, the spare testing capacity is likely to be considerably lower.

Taken together, this means that although Xpert® Xpress SARS-CoV-2 is a potentially promising option for testing a limited number of samples (e.g. from patients in intensive care units or from health-care workers with the highest public health priority), it is probably not the optimal solution for the vast majority of samples, particularly in settings with large outbreaks. The Xpert® Xpress SARS-CoV-2 cartridge is probably best suited to complement a wider testing strategy that primarily relies on one or more higher throughput assays. Indeed, the latter strategy has been adopted by all countries that have or are currently experiencing large-scale disease transmission. In this context, it should be noted that no single high-throughput assay is considered optimal. Countries must assess the capacity of existing platforms, taking into account the aforementioned considerations for Xpert® Xpress SARS-CoV-2, to decide which assay(s) to select.

Testing for COVID-19 and TB

On 20 March 2020 the WHO Global TB Programme circulated an information note on TB and the COVID-19 response stating that, on a programmatic level, countries would need to develop targeted strategies for COVID-19 testing in TB patients, including those with previous disease (12). It also points out that testing for TB in individuals presenting for COVID-19 testing is becoming necessary, as is COVID-19 testing among individuals presenting to TB services with respiratory signs and symptoms.

Next steps

While awaiting additional regional and national approval for Xpert® Xpress SARS-CoV-2, as well as production of the first cartridges, core group members of the European Laboratory Initiative on TB, HIV and Viral Hepatitis (ELI) will focus on the following major areas to provide further

clarification and to support the WHO European Region with materials to be ready once this test becomes available in countries (in order of priority):

- identify and share the list of supplies that will be needed to run the test (e.g. viral transport tube, swabs);
- provide standard operating procedures in English and Russian;
- develop technical support materials to help countries rationalize their laboratory network and use the existing GeneXpert® machines for the maximal COVID-19 response without compromising their use for TB, HIV and viral hepatitis;
- provide remote or in-country support:
 - on necessary biosafety measures and considerations;
 - on workflow organization for GeneXpert® machines that will be used for several diseases (i.e. TB, HIV/viral hepatitis and COVID-19);
 - for sample transportation;
 - on data management tools (e.g. GxAlert) and laboratory record and report forms; and
 - for integration of rapid diagnostic tests into the overall diagnostic algorithms and testing strategies.

Acknowledgements

This rapid communication was developed as a collaborative product by ELI core group members. Document development was guided by Dr Masoud Dara (WHO Regional Office for Europe) and led by Dr Soudeh Ehsani (WHO Regional Office for Europe), ELI chair, Professor Francis Drobniowski (Imperial College London, United Kingdom), and ELI core group members (in alphabetical order), Dr Ana Avellon (National Center of Microbiology, Carlos III Health Institute, Spain), Ms Zamira Baydulloeva (Project HOPE USAID TB Control Program, Tajikistan), Dr Vladimir Chulanov (Reference Center for Viral Hepatitis, Central Research Institute of Epidemiology, Russian Federation), Dr Daniela M. Cirillo (WHO Collaborating Centre in Tuberculosis Laboratory Strengthening and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Italy), Dr Irina Felker (Novosibirsk Tuberculosis Research Institute–WHO Collaborative Centre, Russian Federation), Professor Sven Hoffner (Karolinska Institute, Sweden), Dr Gulmira I. Kalmambetova (National Reference Laboratory, Kyrgyzstan), Dr Dmitry Kireev (Central Research Institute of Epidemiology, Russian Federation), Dr Claudio Köser (University of Cambridge, United Kingdom), Dr Florian Maurer (National and Supranational Reference Center for Mycobacteria, Research Center Borstel–Leibniz Lung Center, Germany), Professor Stefan Niemann (Research Center Borstel–Leibniz Lung Center, Germany), Ms Ecaterina Noroc (Dermatology and Communicable Diseases Hospital, Republic of Moldova), Dr Roger Paredes (Hospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Spain), Dr Rob Schuurman (University Medical Centre Utrecht, The Netherlands), Dr Elina V. Sevastyanova (Central Tuberculosis Research Institute Excellence as part of the WHO TB Supranational Reference Laboratory Network, Central TB Research Institute, Russian Federation), Dr Natalia Shubladze (National Centre of Tuberculosis and Lung Diseases and the National Reference Mycobacteriology Laboratory, Georgia), Mr Daniel Simoes (Institute of Public Health of the University of Porto, Portugal), Dr Alena Skrahina (Republican Research and Practical Centre for Pulmonology and Tuberculosis, Belarus) and Dr Maja Stanojevic (HIV/AIDS National Reference Laboratory, University of Belgrade Medical Faculty, Serbia). The document was reviewed at the WHO Regional Office for Europe by Dr Nedret Emiroglu, Dr Dorit Nitzan, Dr Caroline Brown, Dr Dmitriy Pereyaslov, Dr Christine Uhlenhaut and Dr Joanna Zwetyenga. Furthermore, Dr Karin Weyer and Dr Dennis Falzon from WHO headquarters reviewed the document and provided substantial input.

References

1. Laboratory testing strategy recommendations for COVID-19. Interim guidance: 22 March 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf, accessed 31 March 2020).
2. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans. Geneva: World Health Organization; 2020 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>, accessed 31 March 2020).
3. SARS-CoV-2 diagnostic pipeline. In: FIND. Geneva: Foundation for Innovative New Diagnostics; 2020 (<https://www.finddx.org/covid-19/pipeline>, accessed 31 March 2020).
4. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. OJ. 1998;1–37;L331 (Document 31998L0079; <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A31998L0079>, accessed 31 March 2020).
5. FIND evaluation update: SARS-CoV-2 molecular diagnostics. In: FIND. Geneva: Foundation for Innovative New Diagnostics; 2020 (<https://www.finddx.org/covid-19/sarscov2-eval-molecular>, accessed 31 March 2020).
6. Xpert® Xpress SARS-CoV-2: instructions for use. Sunnyvale (CA): Cepheid; 2020 (<https://www.fda.gov/media/136314/download>, accessed 31 March 2020).
7. March 2020. Diagnostics catalog. Geneva: Stop TB Partnership Global Drug Facility; 2020 (<http://www.stoptb.org/assets/documents/gdf/drugsupply/GFDDiagnosticsCatalog.pdf>, accessed 31 March 2020).
8. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Geneva: World Health Organization; 2020 (Policy update; https://apps.who.int/iris/bitstream/handle/10665/112472/9789241506335_eng.pdf?sequence=1, accessed 31 March 2020).
9. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19). Interim guidance: 12 February 2020. Geneva: World Health Organization; 2020 (<https://apps.who.int/iris/bitstream/handle/10665/331138/WHO-WPE-GIH-2020.1-eng.pdf?sequence=1&isAllowed=y>, accessed 31 March 2020).
10. Emergency Use Listing (EUL): weekly update. Update on submission of applications to the WHO EUL for SARS-CoV-2 Virus IVDs. Summary of activities: 31 March 2020. Geneva: World Health Organization; 2020 (https://www.who.int/diagnostics_laboratory/200331_eul_covid19_ivd_update.pdf, accessed 31 March 2020).
11. Emergency Use Listing procedure: version 8 January 2020. Geneva: World Health Organization; 2020 (https://www.who.int/diagnostics_laboratory/eual/200110_new_eul_procedure_final.pdf?ua=1, accessed 31 March 2020).
12. World Health Organization (WHO) information note tuberculosis and COVID-19. Date: 20th March 2020. Geneva: World Health Organization; 2020 (https://www.who.int/tb/COVID_19considerations_tuberculosis_services.pdf, accessed 31 March 2020).

The WHO Regional Office for Europe

The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves.

Member States

Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
North Macedonia
Norway
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan

World Health Organization Regional Office for Europe

UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark

Tel.: +45 45 33 70 00 Fax: +45 45 33 70 01

Email: eurocontact@who.int

Website: www.euro.who.int